ישראל - עברית - Ministry of Health

taro international ltd, israel - cinacalcet as hydrochloride - טבליות מצופות פילם - cinacalcet as hydrochloride 90 mg - cinacalcet

ישראל - עברית - Ministry of Health

taro international ltd, israel - cinacalcet as hydrochloride - טבליות מצופות פילם - cinacalcet as hydrochloride 90 mg - cinacalcet

ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - metformin hydrochloride; sitagliptin as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 1000 mg; sitagliptin as hydrochloride 50 mg - metformin and sitagliptin

ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - metformin hydrochloride; sitagliptin as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; sitagliptin as hydrochloride 50 mg - metformin and sitagliptin

ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - metformin hydrochloride; sitagliptin as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 500 mg; sitagliptin as hydrochloride 50 mg - metformin and sitagliptin

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

ישראל - עברית - Ministry of Health

naomi shaco-ezra ltd - buprenorphine hydrochloride; naloxone hydrochloride dihydrate - טבליות למתן מתחת ללשון - buprenorphine hydrochloride 2.16 mg; naloxone hydrochloride dihydrate 0.61 mg - buprenorphine - buprenorphine - substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. the intention of the naloxone component is to deter intravenous misuse.treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

ישראל - עברית - Ministry of Health

naomi shaco-ezra ltd - buprenorphine hydrochloride; naloxone hydrochloride dihydrate - טבליות למתן מתחת ללשון - buprenorphine hydrochloride 8.64 mg; naloxone hydrochloride dihydrate 2.44 mg - buprenorphine - buprenorphine - substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. the intention of the naloxone component is to deter intravenous misuse.treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction

ישראל - עברית - Ministry of Health

perrigo israel agencies ltd - milnacipran hydrochloride - קפסולות - milnacipran hydrochloride 50.0 mg - milnacipran - milnacipran - treatment of major (i.e. all characteristics) depressive episodes in adults over 18 years old.

ישראל - עברית - Ministry of Health

trima israel pharmaceutical products maabarot ltd - pseudoephedrine hydrochloride; triprolidine hydrochlride - טבליות מצופות פילם - pseudoephedrine hydrochloride 60 mg; triprolidine hydrochlride 2.5 mg - triprolidine - triprolidine - for the relief of congestion such as rhinitis and associated allergic conditions.